ADC Development: Preclinical Pharmacology Essentials

Antibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer cell populations.  The ability of ADCs to deliver highly potent cytotoxic payloads directly to cancer cells that express a target antigen makes them a promising approach for targeted therapy.  However, the complex structure and mechanism of action of ADCs create significant challenges in their characterization and development.

WuXi Biology offers a comprehensive portfolio to support the development of antibody-drug conjugates.  Our deep expertise in emerging ADC targets further enhances these capabilities, allowing us to deliver integrated scientific support across a broad range of tumor types.